A Study of TYRA-300 in Children With Achondroplasia: BEACH301

Inclusion Criteria

• •Aged 3 to 10 years old (inclusive) at the time of consent.
• •Informed consent provided by parent(s) or legal guardian(s). As study participants are less than 18 years old, participants are willing and able to provide written assent (where applicable and required).
• •Molecular diagnosis of achondroplasia (FGFR3 G380R).
• •Radiographically confirmed open growth plates at Screening, as determined by bone age X-ray.
• •Able to stand and ambulate independently.
• •Able to take oral medication.
• •Sentinel Safety Cohort only: aged 5 to 10 years old (inclusive).
• •Cohort 1 only: aged 3 to 10 years old (inclusive) and are naive to prior growth accelerating therapy.
• •Cohort 2 only: aged 3 to 10 years old (inclusive) and have received prior growth accelerating therapy.